Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kotseva K, et al. Lancet 2009;373:929-40

Published byLester Neal Modified over 5 years ago

Similar presentations

Presentation on theme: "Kotseva K, et al. Lancet 2009;373:929-40"— Presentation transcript:

1 Kotseva K, et al. Lancet 2009;373:929-40

2 Smoking, overweight, and obesity by survey, country, diagnosis, and sex
Kotseva K, et al. Lancet 2009;373:929-40

3 Raised blood pressure, high cholesterol concentration, and diabetes mellitus by survey, country, diagnosis, and sex Kotseva K, et al. Lancet 2009;373:929-40

4 Comparison of the three EUROASPIRE studies
Kotseva K, et al. Lancet 2009;373:929-40

5 Frequency of smoking by age and sex (Error bars show 95% Cis)
Kotseva K, et al. Lancet 2009;373:929-40

6 Patients with therapeutic control of blood pressure
Patients with therapeutic control of blood pressure* at interview by survey, country, sex, and diagnostic category Kotseva K, et al. Lancet 2009;373:929-40

7 Patients with therapeutic control of cholesterol
Patients with therapeutic control of cholesterol* at interview by survey, country, sex, and diagnostic category Kotseva K, et al. Lancet 2009;373:929-40

8 Cardioprotective drug treatment by survey, country, sex, and diagnosis
Kotseva K, et al. Lancet 2009;373:929-40

Download ppt "Kotseva K, et al. Lancet 2009;373:929-40"

Similar presentations

Key messages Stephen S Lim, et al. Lancet 2007; 370: 2054-62.

Key messages Stephen S Lim, et al. Lancet 2007; 370:
Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]
Pai JK et al. N Engl J Med 2004; 351:2599-2610. Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
From: Statins and Cognitive FunctionA Systematic Review

From: Statins and Cognitive FunctionA Systematic Review
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people  Dr Anoop Dinesh Shah, MRCP, Claudia Langenberg, PhD, Eleni.

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people  Dr Anoop Dinesh Shah, MRCP, Claudia Langenberg, PhD, Eleni.
Prevalence and control of cardiovascular risk factors using a German sample – Findings from the STAAB Cohort Study Theresa Tiffe1,3, Götz Gelbrich1,2,

Prevalence and control of cardiovascular risk factors using a German sample – Findings from the STAAB Cohort Study Theresa Tiffe1,3, Götz Gelbrich1,2,
An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in.

An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’
Change (with 95% CI) in outcomes by duration of type 2 diabetes

Change (with 95% CI) in outcomes by duration of type 2 diabetes
Volume 375, Issue 9709, Pages (January 2010)

Volume 375, Issue 9709, Pages (January 2010)
Figure 5 Risk factor control in the intensive treatment group

Figure 5 Risk factor control in the intensive treatment group
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Franklin SS, et al. Circulation 2009;119:243-50

Franklin SS, et al. Circulation 2009;119:243-50

Similar presentations

Ads by Google